Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

Trial Profile

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Amphotericin B liposomal (Primary)
  • Indications Aspergillosis; Lung disorders; Respiratory hypersensitivity; Respiratory tract infections
  • Focus Therapeutic Use
  • Acronyms NEBULAMB
  • Most Recent Events

    • 11 Jan 2017 Planned number of patients changed from 145 to 165.
    • 11 Jan 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Mar 2020.
    • 10 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top